You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

383 Results
Guidelines and Advice
Status: Current
ID: PET 2023-1
Nov 2023
Statistical Reports
Jan 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
epcoritamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Document
May 2024
Document
May 2024
Document
May 2024
Document
May 2024
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport d'activité...
The following information answers many of the questions primary care physicians commonly ask about registration and ONE ID.
Les informations suivantes répondent à de nombreuses questions fréquemment posées par les médecins de première ligne au sujet du rapport MaPratique...
Document
Jun 2024

Pages